Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Midatech Pharma plc
  6. News
  7. Summary
    MTPH   GB00BKT14T00

MIDATECH PHARMA PLC

(MTPH)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensus 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Midatech Pharma plc Announces Executive Changes

07/12/2021 | 09:30am EDT

Midatech Pharma PLC announced the appointment of Dr. Dmitry Zamoryakhin as Chief Scientific Officer, a non-board role, with immediate effect. Dr. Zamoryakhin has broad experience across all phases of development of drugs and medical devices, working with regulatory authorities including the EMA, FDA, PMDA, and NMPA. Most recently, he was Chief Medical Officer of Oxford Biomedica plc, having previously held positions of increasing responsibility at Grunenthal GmbH, Daiichi Sankyo Company Limited, Ono Pharmaceutical Co., Limited and GlaxoSmithKline plc. Dr. Zamoryakhin will take over from Steve Damment, EVP R&D who, after six years with the Company, has decided to retire from full-time employment at the end of September 2021.


© S&P Capital IQ 2021
All news about MIDATECH PHARMA PLC
09/17FTSE 100 Closes Friday Down as Markets Remain Under Pressure
DJ
09/17MIDATECH PHARMA : (“Midatech” or the “Company”) (Form 6-..
PU
09/17FTSE Rises, Weak Retail Sales Could Hamper Sterling's Rise
DJ
08/18MIDATECH PHARMA : Result of 2021 Annual General Meeting (Form 6-K)
PU
07/21MIDATECH PHARMA : welcomes Dr Dmitry Zamoryakhin as Chief Scientific Officer
AQ
07/12Midatech Pharma plc Announces Executive Changes
CI
06/29MIDATECH PHARMA : UK Placing to Raise £10.0 million (Form 6-K)
PU
06/29FTSE 100 Rises 0.3% as Construction Stocks Gain
DJ
06/29MIDATECH PHARMA : Corporate Overview
PU
06/29FTSE 100 Tipped to Open Lower After Mixed Asia, U.S. Sessions
DJ
More news
Financials
Sales 2020 0,34 M 0,47 M 0,47 M
Net income 2020 -22,2 M -30,5 M -30,5 M
Net cash 2020 7,21 M 9,91 M 9,91 M
P/E ratio 2020 -0,51x
Yield 2020 -
Capitalization 26,8 M 36,9 M 36,9 M
EV / Sales 2019 13,7x
EV / Sales 2020 27,7x
Nbr of Employees 18
Free-Float 87,0%
Chart MIDATECH PHARMA PLC
Duration : Period :
Midatech Pharma plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIDATECH PHARMA PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,27 
Average target price
Spread / Average Target -
Managers and Directors
Stephen Anthony Stamp Director, Chief Executive & Financial Officer
Rolf Stahel Non-Executive Chairman
Steve Damment Executive Vice President-Research & Development
Dmitry Zamoryakhin Chief Scientific Officer
Sijmen de Vries Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MIDATECH PHARMA PLC2.83%37
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850